Business context and reporting period
Roivant Sciences Ltd. is a Bermuda-incorporated, early commercial-stage biopharmaceutical and healthcare technology company that develops medicines through subsidiary businesses (“Vants”). This is its Form 10-K for the fiscal year ended March 31, 2022—not a report for calendar 2020 Q4. The filing compares fiscal 2022 with fiscal 2021. Roivant’s common shares began trading on Nasdaq in October 2021.
At fiscal year-end, VTAMA (tapinarof) had not yet generated commercial product revenue. The FDA approved it for adult plaque psoriasis in May 2022, after the reporting period; Dermavant launched it that month. The pipeline included programs at commercial, Phase 3, Phase 2/3, Phase 2 and Phase 1/2 stages.
Key financial metrics
| Metric | FY ended Mar. 31, 2022 | FY ended Mar. 31, 2021 |
|---|---|---|
| Revenue | $55.3 million | $23.8 million |
| Operating expenses | $1,406.9 million | $1,094.7 million |
| Loss from operations | $(1,351.6) million | $(1,070.9) million |
| Net loss | $(924.1) million | $(900.2) million |
| Net loss attributable to Roivant | $(845.3) million | $(809.2) million |
| Basic and diluted loss per share | $(1.26) | $(1.28) |
| Net cash used in operations | $(677.7) million | $(552.1) million |
| Cash and cash equivalents at year-end | $2,060.4 million | $2,055.0 million |
| Long-term debt, net carrying amount | $210.0 million | $170.3 million |
Revenue was primarily from licensing arrangements and technology subscription and service fees; the filing says revenue through March 31, 2022 was not significant and reports no product-sale revenue. A product gross margin is therefore not a meaningful indicator for this period. Cash, cash equivalents and restricted cash totaled $2,074.0 million at year-end. Total assets were $2,585.1 million and current liabilities were $184.4 million. The filing states cash on hand was expected to fund committed operating expenses and capital needs for at least 12 months from issuance of the financial statements, based on current plans and forecasts.
Material changes versus the prior year
- Revenue rose $31.5 million, but operating expenses increased $312.2 million and operating loss widened $280.7 million. Net loss increased $23.9 million.
- Research and development expense more than doubled to $483.0 million, reflecting program progression, increased personnel and higher share-based compensation.
- General and administrative expense rose to $775.0 million, primarily because of $438.9 million of additional share-based compensation expense. Total share-based compensation was $565.0 million, including a $372.9 million catch-up expense after liquidity vesting conditions were met in the September 2021 business combination.
- Acquired in-process R&D expense fell to $139.9 million from $596.1 million, as the prior year included major acquisitions and asset transactions. Fiscal 2022 included $82.1 million for brepocitinib, $14.1 million for RVT-2001 and a $39.3 million tapinarof milestone expense.
- Operating cash use increased $125.6 million. Investing activities provided $303.3 million, largely reflecting approximately $320 million received in the Datavant merger; financing activities provided $306.8 million.
Outlook, risks and unusual items
- Commercialization and capital: Management expected higher spending as it built commercial capabilities for VTAMA and advanced its pipeline. The company warned it may require additional capital and may not achieve profitability. In June 2022, after FDA approval, Dermavant received $160 million under a revenue-interest arrangement, in exchange for a capped share of future U.S. VTAMA revenues. The proceeds were intended primarily to fund milestone obligations, including approximately $126 million to GSK and approximately $20 million to Welichem.
- Pipeline and cost actions: Roivant said it was reprioritizing its pipeline and discontinuing several programs, including ARU-1801, LSVT-1701, DMVT-502, DMVT-503, DMVT-504 and CVT-TCR-01. Management expected to direct capital toward selected programs, including those at Priovant.
- Clinical and safety risk: Batoclimab development had been paused in early studies after observed increases in total cholesterol and LDL. Development resumed after safety review and regulatory discussions; the filing describes an ongoing atorvastatin interaction study and preliminary evidence that atorvastatin may counter the LDL increase. Clinical outcomes and long-term safety remain uncertain.
- Other material risks: The business depends on successful clinical trials, regulatory approvals, VTAMA adoption and reimbursement, third-party manufacturing and supply, and intellectual-property protection. COVID-19 had caused some clinical delays, though management reported no material financial impact through the filing date. Drug-pricing and reimbursement changes, competition, financing needs and litigation are also identified risks.
- Unusual and non-cash items: The fiscal 2022 results included a $443.8 million gain associated with the Datavant merger and remeasurement of the retained investment, and a $66.5 million gain on termination of Sumitomo options. The Datavant transaction generated approximately $320 million of cash proceeds; the accounting gain is not equivalent to cash received.
- Litigation and controls: The filing describes an Immunovant securities class action, including claims against Roivant, and patent-related disputes involving Genevant, Arbutus, Moderna and Acuitas. Roivant said it intended to defend the matters; it had not recorded a liability for the disclosed claims. Management concluded disclosure controls were effective. The auditor issued an unqualified opinion on the financial statements, but did not attest to internal-control effectiveness because of the newly public company transition period.
Important facts for investors to verify
- VTAMA’s post-approval launch performance, pricing, access and reimbursement, and the resulting revenue-interest payments and milestone obligations.
- Cash burn and available liquidity after the fiscal year-end, including the June 2022 funding, milestone payments, debt service and commercial launch spending.
- Progress, timing and results of key clinical programs—especially batoclimab, brepocitinib, namilumab and RVT-2001—and any updated safety findings.
- The composition and volatility of reported earnings, particularly share-based compensation and gains from investments or transactions versus recurring operating performance.
- Developments in the disclosed securities and patent litigation, and any impact on costs, intellectual property rights or commercialization.